Aethlon Medical (NASDAQ: AEMD) is one of 23 publicly-traded companies in the “Analytical instruments” industry, but how does it compare to its peers? We will compare Aethlon Medical to similar businesses based on the strength of its risk, institutional ownership, profitability, dividends, earnings, analyst recommendations and valuation.
Insider and Institutional Ownership
7.4% of Aethlon Medical shares are owned by institutional investors. Comparatively, 62.9% of shares of all “Analytical instruments” companies are owned by institutional investors. 6.6% of Aethlon Medical shares are owned by insiders. Comparatively, 14.6% of shares of all “Analytical instruments” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Aethlon Medical and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aethlon Medical Competitors||-190.83%||-33.65%||-15.46%|
Earnings and Valuation
This table compares Aethlon Medical and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aethlon Medical||$150,000.00||-$5.67 million||-2.30|
|Aethlon Medical Competitors||$1.08 billion||$109.59 million||24.99|
Aethlon Medical’s peers have higher revenue and earnings than Aethlon Medical. Aethlon Medical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Aethlon Medical has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Comparatively, Aethlon Medical’s peers have a beta of 1.10, indicating that their average stock price is 10% more volatile than the S&P 500.
This is a summary of current ratings and recommmendations for Aethlon Medical and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aethlon Medical Competitors||117||737||1092||51||2.54|
Aethlon Medical currently has a consensus price target of $3.00, suggesting a potential upside of 183.02%. As a group, “Analytical instruments” companies have a potential upside of 4.44%. Given Aethlon Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Aethlon Medical is more favorable than its peers.
Aethlon Medical peers beat Aethlon Medical on 8 of the 13 factors compared.
About Aethlon Medical
Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosomal biomarkers to diagnose and monitor life-threatening disease conditions, such as cancer and neurological disorders; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection. The company was founded in 1991 and is based in San Diego, California.
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.